Norfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

Comparative Study of Norfloxacin Versus Norfloxacin With Itopride in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04161768

Enrollment

Registered

2019-11-13

Start date

2018-12-01

Completion date

2028-12-01

Last updated

2019-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spontaneous Bacterial Peritonitis

Brief summary

Norfloxacin versus Norfloxacin with Itopride in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

Detailed description

Comparative Study of Norfloxacin versus Norfloxacin with Itopride in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

Interventions

DRUGNorfloxacin

Norfloxacin 400 mg daily

DRUGItopride

Itopride 50 mg three times daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* cirrhotic patients with ascites who had previous episodes of SBP.

Exclusion criteria

* 1\. Allergy or contraindication for the used drugs. 2. Recent antibiotics therapy in the previous 2 weeks. 3. Patients with hepatocellular carcinoma or other neoplasia. 4. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame	Description
Number of bouts of recurrence during treatment.	6 months	The recurrence of infection during treatment.

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, ass. prof.

sheriefabdelsalam@yahoo.com00201147773440

Backup Contactsherief abd-elsalam, ass. prof.

sherif_tropical@yahoo.com00201147773440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026